ID: ALA3586434

Max Phase: Preclinical

Molecular Formula: C21H22FN7O

Molecular Weight: 407.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4ccc(F)cc4-n4nccn4)C[C@H]3C2)n1

Standard InChI:  InChI=1S/C21H22FN7O/c1-13-7-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)18-4-3-17(22)8-19(18)29-23-5-6-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+

Standard InChI Key:  ILQWQOBQPYXUMR-IYBDPMFKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 407.45

Molecular Weight (Monoisotopic): 407.1870

AlogP: 2.02

#Rotatable Bonds: 3

Polar Surface Area: 80.04

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.99

CX LogP: 1.14

CX LogD: 1.14

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.66

Np Likeness Score: -1.53

References

1. Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman BT, Young LK, Yun S..  (2015)  Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.,  58  (14): [PMID:26087021] [10.1021/acs.jmedchem.5b00742]

Source

Source(1):

• Scientific Literature